Tests a topical cannabidiol roll-on for migraine attacks
Tests a cannabidiol roll-on on the skin in adults with migraine.
Plain-language title generated from the registry record
Registry title: Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Key facts
- Where
- Tehran, IranSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07093138, who can take part
Where in Iran
- Tehran Province, Tehran, Imam Khomeini Street (RA) - Before Hassan Abad SquareTehran, IranTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alasht Pharmed
- Trial code
- NCT07093138
- Record updated
- 30 July 2025
- Original description
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.Read full original descriptionShow less
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.
The primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).
Secondary objectives included evaluating additional efficacy and safety outcomes of Canvert-M in managing migraine attacks.
Inclusion: Males and females with age of 18 to 55 years; Age of migraine onset ˂ 50 years; Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year; Having a history of 2-8 attacks per month; Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period; Using effective contraception by the women of childbearing potential during the study; Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments.
Exclusion: Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M; Treatment with any investigational agent within 30 days prior to screening; Having a diagnosis of other primary (cluster and tension) and secondary headache disorders; Having a history of chronic migraine headache; History of resistant or refractory migraine headaches based on European Headache Federation consensus; History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results; History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil; History of substance use disorders; The presence of any skin lesions in the areas where the product is used; Nursing mothers, pregnant women, and women who plan to become pregnant during the study period; Taking carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, and warfarin within 14 days of the study procedure.